Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

A serial entrepreneur and a promising drug emerge from failed companies to pursue subsets of obesity patients, with or ...

Wen Shuhao helped speed up the development of Pfizer’s Covid oral drug, Paxlovid. Now the chairman of Xtalpi wants to help ...

Dublin-based accessibility start-up Mobility Mojo will receive €4.25m in investment from UK-based equity investor Gresham ...

Liberty Mutual Investments—the investment firm of Liberty Mutual Group of Insurance Cos.—is building on an existing partnership with Affirm. Over the program term, through June 2027, the investment ...

The U.S. telecom major is planning to exit a majority of its copper network operations by 2029 as customers shift to newer ...

China has become a key piece of Foresite Capital’s investment and company formation strategy. During the J.P. Morgan Healthcare Conference, Managing Director Michael Rome shared his thoughts on why ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

This collaboration between Eli Lilly and a Top VC fund can redefine how Corporate VC (CVC) fuels innovation – not just in ...

Purdue partners with Eli Lilly and Merck to launch the Young Institute Pharmaceutical Manufacturing Consortium, focusing on sterile injectables.

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...